India’s orthopaedic and cardiac implant sector is poised for significant growth, with its market size expected to reach USD 4.5–5 billion by FY2027–28, according to a recent report by CareEdge Ratings. This expansion is being fueled by robust domestic demand and a steady rise in exports.
As per the report, the sector, including exports, was valued at USD 2.4–2.7 billion in FY24. The growth is being driven by a confluence of factors: rising per capita income, greater awareness of healthcare needs, an ageing population, expanding medical infrastructure and wider insurance penetration.
The implant segment in India has historically been dominated by foreign multinational companies (MNCs), which largely rely on imports to cater to the Indian market. These MNCs benefit from advanced technology, established safety records, strong marketing networks and robust after-sales service. However, domestic manufacturers are rapidly narrowing the gap.
According to CareEdge Ratings, Indian implant makers have outpaced their foreign counterparts, registering a compound annual growth rate (CAGR) of 28 per cent over the past four years (FY20–FY24). Export growth from domestic players stood even higher at 37 per cent CAGR during the same period, compared to a modest 12 per cent CAGR recorded by foreign MNCs.
The surge in homegrown implant sales is largely attributed to their cost-effectiveness, growing reputation for safety and efficacy, and stronger involvement in government-backed insurance schemes. This volume-driven growth has enabled domestic manufacturers not only to capture a bigger share of the Indian market but also to begin making inroads globally.
The sector’s potential has caught the attention of large pharmaceutical companies as well. Industry majors like Zydus Lifesciences Limited and Alkem Laboratories Limited have announced strategic investments in implant manufacturing and distribution, signalling rising confidence in the sector’s future.
“The medical implant sector in India is on a robust growth trajectory. With strong domestic demand and expanding exports, the market is expected to grow at a CAGR of 15–16 per cent and reach up to USD 5 billion by FY28,” said Krunal Modi, Director at CareEdge Ratings. “Supportive government policies and infrastructure growth are steadily pushing the sector towards self-reliance and Atmanirbharta.”
However, the report also cautioned against several challenges that could temper growth. These include regulatory hurdles, patent disputes, price cap regulations, and global trade and tariff uncertainties.
